History and progress of antiviral drugs: from acyclovir

to direct-acting antiviral agents (DAAs) for Hepatitis C by Bryan Marrugo, Owen Lloyd et al.
Medicina Universitaria. 2015;17(68):165--174
www.elsevier.es/rmuanl
REVIEW ARTICLE
History  and progress  of antiviral  drugs:  From acyclovir
to direct-acting  antiviral  agents  (DAAs)  for Hepatitis  C
O.L. Bryan-Marrugo a, J. Ramos-Jiménezb, H. Barrera-Saldan˜a a, A. Rojas-Martínez a,
R.  Vidaltamayo c, A.M. Rivas-Estilla a,∗
a Department  of Biochemistry  and  Molecular  Medicine,  School  of Medicine,  ‘‘Dr.  José  Eleuterio  González’’,  University  Hospital,
Universidad Autónoma  de Nuevo  León,  Monterrey,  N.L.,  Mexico
b Department  of  Internal  Medicine,  School  of Medicine,  ‘‘Dr.  José  Eleuterio  González’’,  University  Hospital,  Universidad
Autónoma  de Nuevo  León,  Monterrey,  N.L.,  Mexico
c Universidad  de  Monterrey,  Monterrey,  N.L.,  Mexico
Received  17  December  2014;  accepted  12  May  2015
Available  online  3 July  2015
KEYWORDS
Hepatitis  C  virus;
Antiviral  drugs;
Direct-acting
antiviral  agents
(DAAs)
Abstract  The  development  of  antiviral  drugs  is a  very  complex  process.  Currently,  around  50
drugs have  been  approved  for  human  use  against  viruses  such  as  HSV,  HIV-1,  the cytomegalo
virus, the influenza  virus,  HBV  and  HCV.  Advancements  in this  area  have been  achieved  through
efforts and technical  breakthroughs  in  different  scientific  fields.  The  improvement  in  the  treat-
ment of HCV  infection  is a  good  example  of  what  is needed  for  efficient  antiviral  therapy.  A
thorough description  of  the  events  that  lead  to  the  development  of  specifically  targeted  antivi-
ral therapy  or  HCV (STAT-C)  could  be useful  to  further  improve  research  for  treating  many  other
viral diseases  in  the  future.  Similar  to  HIV-1  and  HBV  treatment,  combination  therapy  along  with
personalized  medicine  approaches  have  been  necessary  to  successfully  treat  HCV  patients.  This
review is focused  on  what  has  been  done  to  develop  a  successful  HCV therapy  and  the  drawbacks
along the  way.
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Introduction
From  1972  to date,  more  than  50  new  viruses  have  been
identified  as  etiologic  agents  of  human  disease.1 These  new
viral  diseases  have  required  more  sophisticated  therapeutic
agents,  but  the development  process  of  these  strategies  to
this  point  has been slow  and  full  of hurdles.
Antiviral  chemotherapy  has  advanced  at snail-like  pace,
unlike  antibiotics,  which  in 30  years  achieved  an advanced
therapeutic  stage.  34  years  elapsed  from  the description  of
the  antibacterial  molecule  salvarsan,  ‘‘the  magic  bullet’’,
by  Ehlrich  in 1910,2 to  the discovery  of  penicillin  by  Fleming
in  1929,3 to  Domagk’s  description  of  prontosil,  the precursor
of  sulfonamides  in 19354 and  the  isolation  of  streptomycin,
chloramphenicol,  erythromycin  and  tetracycline  by  Waks-
man  in  1944.5 However,  it took  almost  60  years  for  antiviral
development  to reach its  current  status  of  effectiveness.
The  evolution  of  the treatment  for Hepatitis  C  is  a good
example  of  how  complex  antiviral  development  can  be and
how  a  combined  and  specific  targeted  antiviral  therapy  has
proved  to  be  the  best approach  to  follow  for  viral  disease
treatment.
The  Hepatitis  C  virus  (HCV)  affects  over 170  million  indi-
viduals  worldwide,  80%  of  which are chronically  infected.6
This  is four  times  the number  of  people  infected  with  HIV
and  about  half  the number  of  persons  infected  with  the
Hepatitis  B  virus  (HBV). 7 HCV is  caused  by  a hepatotropic
virus,  which  belongs  to  the Flaviviridae  family,  genus  Hep-
acivirus.  HCV was  discovered  in 1989  and  its viral  genome  is a
9.6  kb-long  positive  single-stranded  RNA.  It  encodes  a single
polyprotein  precursor  of  3010  amino  acids  and  has an inter-
nal  ribosome  entry  site  at the 5′ untranslated  region.  This
polyprotein  precursor  is  co-translationally  processed  by  cel-
lular  and  viral  proteases  into  three  structural  proteins  (core,
E1 and  E2)  and seven  non-structural  proteins  (p7, NS2,  NS3,
NS4A,  NS4B,  NS5A  and  NS5B).8 The  structural  proteins  asso-
ciate  with  the genomic  RNA  and  a viral  particle  is  assembled
inside  a  lipidic  envelope.
Treatment  for HCV  infection  has  come  a  long  way.
Between  2001  and  2011,  a standard  of  care  (SOC)  for chronic
HCV  infection  was  established  worldwide.  It consisted  of
a  combination  of  pegylated  interferon  (PEG-IFN)  and  riba-
virin  (RBV).  Nowadays,  new  specific  antiviral  agents  have
been  approved.  In  May  2011, boceprevir  and  telaprevir,  two
first-generation  NS3/4A  protease  inhibitors,  were  autho-
rized  for  their  use  in combination  with  PEG-IFN  and  RBV
for  a  24-to-48-week  course  of  treatment  in HCV-genotype
1  infections.  Two  years  later  (December  2013),  Simepre-
vir  (a  second-generation  NS3/4A  protease  inhibitor)  was
approved  for  use  with  PEG-IFN  and  RBV  for  a 12-week
course  of  treatment  in HCV-genotype  1, while  sofosbu-
vir  (a NS5B  nucleotide  polymerase  inhibitor)  was  approved
for  use  with  PEG-IFN  and/or  RBV  for  a 12/24-week  course
of  treatment  in HCV-genotypes  1 to  4.  IFN-free  regimens
have  been  shown  to  give  better  results,  because  sofos-
buvir,  combined  with  simeprevir  or  an NS5A  replication
complex  inhibitor  (ledipasvir  or  daclatasvir),  with  or  with-
out  RBV  for  a  12-week  treatment  in genotype  1, resulted
in  a  sustained  virological  response  (SVR)  >90%.  In  addition,
ABT-450/r  (ritonavir-boosted  NS3/4A  protease  inhibitor)-
based  regimens,  in  combination  with  other  direct-acting
antiviral  agent(s)  with  or  without  RBV  for  12  weeks  in
genotype  1, have  demonstrated  similar  results  regarding
SVR.9
Roadblocks for antiviral  drug development
As  we  see  in  the  text above,  therapy  for HCV  infection
remained  almost  the  same  from  2001  to  2011.  After  a decade
of  poorly  effective  HCV therapy,  the  development  of  specific
compounds  against  this virus  ramped  up HCV  treatment  on
a  pace  that nearly  matched  antiretroviral  therapy  for  HIV.
‘‘Why  did it  take  such a  long  time?’’  is  an important  question
whose  answer  could  help  on the  approaches  towards  drug
development  against  untreated  diseases.  The  first  complica-
tion  when studying  a virus  is  the limitations  regarding  in  vitro
systems  and  animal  models  for  experimentation;  second,  is
the  low rate  of  discovery  for  efficient  candidate  molecules,
and  third,  the delicate  balance  between  efficacy,  toxicity
and  resistance  towards  the selected  antiviral  drug.  Addi-
tional  economical  aspects  must  also  be considered.  Here  we
have  analysed  each  of  these  aspects  under  the  light  of  the
promises  and  pitfalls  related  to  Hepatitis  C  research  and
treatment.
HCV study  tools
Viruses  are intracellular  organisms  which  depend  on  cellular
machinery  for replication.  Therefore,  a huge  breakthrough
in this  field  was  achieved  by  Enders,  Robbins  and Weller
in  1951,  when  they  developed  an  in vitro  virus  propaga-
tion  system  in cell  culture.10 Since  then,  many  in vitro  and
in  vivo  systems  have  been  implemented  for  the study  of
several  viruses,  such  as  polio  and  HIV.  Cell  assays  systems
were  recently  developed  for  HCV  infection  and  propaga-
tion.  In  the early  beginnings  of HCV studies,  no  small  animal
model  existed  to study  HCV  infections,  and  Chimpanzees,
the  only animals  capable  of  being  infected  with  HCV,  were
precluded  by both  ethical  and  functional  difficulties.  The
in  vitro  development  for  HCV  research  began  with  the
sub-genomic  replicon  cell  culture system  that  replicates
autonomously  in the human  hepatoma  cell  line  Huh-7  gener-
ated  by  Bartenschlager  et al.,  in 2001.11,12 This  sub-genomic
replicon  model  was  further  improved  by  the  identification
and  introduction  of  adaptive  mutations,  which  enhanced
virus  replication  capacity  and  lead  to  the  establishment  of
the  full-length  replicon  system  using  the  highly  permissive
cell  line  Huh-7.5.1  in  2003,  by  Blight  and Bartenschlager
et  al.,  separately.13--15 These  developments  allowed  the
study  of  HCV  infection  mechanisms,  such as  packaging,  bud-
ding  and  a more  accurate  evaluation  of  potential  antiviral
molecules.  On  the other  hand,  the development  of  a  small
animal  model  that  can be infected  with  HCV  became  a
reality  with  the  T- and  B-cell  deficient  mice  with  severe
combined  immunodeficiency  (SCID),  grafted  with  human
hepatocytes.  The  first  HCV  infection  studies  in  this  model
were  performed  by  Mercer  et al. in 2001.  In  recent  years
the  development  of  transgenic  mice  with  a  chimeric  mouse-
human  liver  revolutionized  HCV  infection  research,  allowing
the assessment  of pathological  and  immunological  profiles
of  the disease.16 Today,  scientists  rely  on a combination  of
antiviral  activity  assessment  in  the  HCV  replicon  cell culture
system,  cell-based  infection  systems,  and  pharmacokinetic
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profiling  in  animals  as  proxy  indicators  of  antiviral  drugs’
efficacy,  before  attempting  clinical  trials.17
Screening process for  antiviral drug discovery
Another  aspect  that  made  antiviral  drug discovery  a diffi-
cult  endeavor  was  the lack  of  a  structured  and  systematic
method  for  antiviral  drug  development.  Three  decades  ago
most  of  the  first  discoveries  of  antiviral  compounds  were
fortuitous,  since  molecules  originally  developed  for  other
purposes  were  selected  as  antiviral  candidates,  based on
their  success  in other  medical  disciplines.  These  meth-
ods  for  antiviral  discovery  were  empirical,  and  most  of
the  time,  the  biological  mechanism  behind  the  observed
antiviral  effect  remained  unclear.  For  instance,  the use  of
thio-semicarbazones  against  the  vaccinia  virus,  described  in
1950  by  Hamre  et  al.,  and used  later  as  an antibacterial  drug
against  tuberculosis.18 In  1959,  the 5-iodo-2-deoxyuridine
(IDU),  which  was  originally  designed  for  cancer  treatment,
proved  to  exhibit  antiviral  activity  against  the Herpes  Virus,
but  due  to  its  high  cytotoxicity,  its  use  was  limited  to  topical
application.  IDU  boosted  antiviral  development,  and  from
its  discovery  many  antiviral  molecules  were  proposed  for
the  treatment  of  various  viral  diseases.19 In Fig. 1,  a  time
line  of the  milestones  in the  development  of  antiviral  agents
shows  the  early  years  of  this  discipline  and how  it  evolved  to
become  a  structured  and methodic  science.20 At  the  time  of
IDU  discovery,  only  a  handful  of  viruses  were  known  to  cause
diseases  in  humans.  The  first  antiviral  drugs  were  directed
to  treat  herpes,  polio,  smallpox  and influenza,  as  they  were
the  most  relevant  viral  diseases  of that  time.  Some  of them
that  we  can  mention  are the following:  triflouro-thymidine
(TFT),  a  nucleoside  analogue  used  to  treat  herpes;  ade-
nine  arabinoside  (Ara-A)  a  nucleoside  analogue  against  the
herpes  simplex  virus21; 2-(-hydroxybenzyl)  benzimidazole
for  the  treatment  of  poliomyelitis;  Marboran  for  the  treat-
ment of smallpox  and  amantadine  and rimantadine  to  treat
influenza,  which  were  identified  by  traditional  biological
screening  assays  in  the early  1960s  and was  shown  to
be  inhibitory  for  influenza  A  viruses  in  cell  culture  and
animal  models.  In  the last  two  decades,  medicinal  chem-
istry  has developed  into  a recognized  discipline,  in which
a  lead  compound  was  usually  identified  by  screening  a
large  collection  of  molecules.  This  method  was  improved
with  the introduction  of combinatorial  chemistry  and  high-
throughput  screening.22 Today,  more  structured  rationales
are  implemented  when  looking  for  new  antiviral  drugs;  sim-
ple  screening,  blind  screening  and  programmed  screening
have  become  more  sophisticated,  as  the  tools  to  ana-
lyze  structure,  protein  interaction  and  viral  behavior  have
evolved.  For HCV therapy  development,  many  attempts  to
treat  the infection  were  implemented,  with  rather  poor
results.23 Due  to  the lack  of  a serological  test, systematic
treatment  protocols  could  not  be  performed,  and  so  several
‘‘informal’’  studies  were  reported,  evaluating  many  kinds  of
molecules.  But  it was  not until  1986  that  Hoofnagle  reported
the  beneficial  effect  of  Interferon  Alpha  in  a  pilot  study  to
treat  Non-A/Non-B  hepatitis.24 This  report  primed  a  boom in
HCV  therapeutics  and many  randomized  controlled  clinical
trials  were  performed  to  improve  HCV  treatment.  In 1990
Ribavirin  was  first  proposed  to  treat  HCV  infection  and the
first clinical  trial  for the assessment  of  its efficacy  began
in  1991.25,26 After  the efficacy  of  the combined  antiviral
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Figure  1  Evolution  of  antiviral  drug  discovery.  From  the  beginnings  of  antiviral  chemotherapy  to  the  comprehensive  design  of
antiviral drugs  (drug  name/year  discovered  or  approved).
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Figure  2  HCV Potential  targets  for  antiviral  chemotherapy.  Many  targets  for  antiviral  action  can  be found  along  HCV’s  life  cycle.
therapy  of Pegylated  Interferon- (PEG-IFN-)  and  ribavirin
against  HCV  infection  was  proven,  it  became  the standard  of
care  (SOC)  for this  disease,  and  despite  its  shortcomings  (50%
response  rate  and  50%  relapse  rate  on  patients  infected  with
genotype  1b, and unwanted  side  effects),  it remained  as
such  for  more  than  15  years.27,28 During  this  time,  using  blind
screening  approaches,  some  molecules  were  found  to reduce
HCV-RNA  levels  in vitro, but  none  of  them  were significant
enough  to be  implemented  clinically.  It  was  not  until  May,
2011  that  the improved  understanding  of the  HCV life  cycle
led  to  the  discovery,  assessment  and  FDA  approval  of  the  HCV
protease  inhibitors  Telaprevir  and  Boceprevir,  that  effec-
tively  reduce  viral  load  on  chronic  HCV  infected  patients,
in  treatment  of  naïve  patients  and  in  prior  relapsers  and
non-responders. 29,30 Telaprevir  and boceprevir  were  the first
direct-acting  antiviral  agents  (DAAs)  that selectively  target
HCV.  However,  new  DDAs  have  been  recently  added  to  this
list:  simeprevir  (protease  inhibitor),  sofosbuvir  (NS5b  poly-
merase  inhibitor),  daclatasvir  (NS5A  protein  inhibitor),  and
faldaprevir  (second-wave  NS3/4A  protease  inhibitor),  all of
them  showing  very  promising  results  and  some  have even
been  proposed  as  the treatment  backbone  for  Interferon-
free  HCV  therapies.31,32 With  these selective  HCV  protease
inhibitors,  the establishment  of STAT-C  therapy  became
a  reality.  Today,  several  DAAs  (including  HCV  protease
inhibitors,  polymerase  inhibitors,  and  NS5A inhibitors)  are in
various  stages  of  clinical  development.  Current  research  is
attempting  to  improve  the pharmacokinetics  and  tolerabil-
ity  of  these  agents,  define  the  best regimens,  and  determine
treatment  strategies  that  produce  the best  outcomes.  Some
of  these  DAAs  will  reach  the  market  simultaneously,  and
resources  will  be  needed  to  guide the use  of these  drugs.  It
is  also  worth  mentioning  that  different  lines  of  research  are
currently  evaluating  other  ways  to  improve  HCV  chemother-
apy.  For  example,  taribavirin,  a  prodrug  for  the long-known
nucleoside  analogue  ribavirin,  is  at  3rd phase  clinical  tri-
als  and  has  shown  promising  results.33 This  new  antiviral
would  further  boost  HCV  therapy  in the coming  years.
Fig.  2  shows  the major  HCV  potential  targets  for  antiviral
chemotherapy.
Efficacy and toxicity on  the  development of an
efficient antiviral drug
Since  the discovery  of  IDU  50  years  ago,  only  a few molecules
have  proven  to  be effective  and  safe when used for  selec-
tive  antiviral  therapy.  A huge  breakthrough  that  came
from  the better  understanding  of  virus-host  interaction  was
the  inception  of 9-(2-hydroxyethoxymethyl)  guanine  (Acy-
clovir).  It was  the first highly  selective  antiviral  drug,  being  a
substrate  for  the  Herpes  Simplex  Virus-encoded  thymidine-
kinase.  It displayed  a  direct  inhibitory  effect  against  viral
replication  and  practically  no  adverse  effects  on  the host.
The  achievement  of  selective  viral  toxicity  by  Acyclovir  and
other  similar  molecules  were  thought  of  as  the beginning
of  a new therapeutic  age  for  a  well-established,  effective
and  safe antiviral  therapy.  Acyclovir  is  a  pro-drug,  which
means  it has  to  be  further  metabolized  in  vivo  before  enter-
ing the  infected  cell  wherein  further  metabolism  may  or
may  not  be required  to  yield  the active  inhibitor.  The  key
to  Acyclovir’s  specificity  is  the selective  phosphorylation
of  the  acyclic  guanosine  nucleoside  by  the  Herpes  virus-
encoded  pyrimidine  deoxynucleoside  kinase,  which  means
it would  only  be active  on  Herpes-infected  cells.34 After
Acyclovir’s  discovery  and  study,  several  nucleoside  analog
pro-drugs  have  been  developed,  all  of them  with  relatively
high  specificity  (Table  1  shows  a  list  of  the most  important
antiviral  drugs,  including  their  mode  of  action).  Sadly,  new
challenges  arose  for  antiviral  treatment.  Several  resistant
mutants  have  been identified,  making  it  more  difficult  to
achieve  a complete  viral  eradication  and therefore  demands
for  a successful  antiviral  therapy  became  more  complex,
involving  many  aspects  that were  previously  not  considered.
One  undeniable  fact is  that  most  of  our  current  knowl-
edge  on  viral  and  antiviral  science  comes  from  the  study  of
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Table  1  Major  antiviral  compounds  developed  and  approved  for  use  in humans.
Name  Class  Target  virus  Year  of  discovery
-Thiosemicarbazone IMINE  DERIVATIVE BROAD  SPECTRUM  1949
INTERFERON  CYTOKINE  (Immunomodulator)  BROAD  SPECTRUM  1954,  1957
IDU NA  HERPES  SIMPLEX  1959
HYDROXYBENZYL-BENZIMIDAZOLE  UD  BROAD  SPECTRUM  1961
MARBORAN  UD  DNA VIRUSES  1963
TFT NA  HERPES  SIMPLEX  1964
AMANTADINE,  RIMANTADINE  UD  INFLUENZA  1964
ARA-A NA  HERPES  SIMPLEX  1964
ACICLOVIR NA  HERPES  1971
RIBAVIRIN NA  BROAD  SPECTRUM 1972
DHPA-dihydroxypropyladenine NA  BROAD  SPECTRUM 1978
Phosphonoformicacid  (FOSCARNET)  PA  HERPES,  CYTOMEGALOVRUS  1979
BVDU (Brivudin)  NA  HERPES  1979
GANCICLOVIR  NA  HERPES,  CYTOMEGALOVRUS  1982
AZIDOTHIMIDINE  (AZT,  zidovudine)  NARTI  HIV 1985
DDC (HIVID,  Zalcitabine)  NARTI  HIV 1986
DDL (VIDEX,  didanosine)  NARTI  HIV 1987
D4T (SERIT,  Stavudine)  NARTI  HIV 1987
CIDOFOVIR  NA  CMV  1988
FAMCICLOVIR  NA  HERPES  SIMPLEX  1989
HEPT/TIBO NNRTI  HIV 1990
NEVIRAPINE  (Viramune)  NNRTI  HIV 1990
3TC (Epivir,  Lamivudine)  NARTI  HIV 1991
SAQUINAVIR  PI  HIV 1991
DOCONASOL  FI  HERPES,  SINCYTIAL  VIRUS  1991
ZANAMIVIR (RELENZA)  NI  INFLUENZA  1993
DELAVIRDINE  (RECRIPTOR)  NNRTI  HIV 1993
INDINAVIR (CRIXIVAN)  PI  HIV 1994
TENOFOVIR NA  HIV 1995
EFIVARENZ NNRTI  HIV 1995
AMPRENAVIR  (AGENERASE) PI  HIV 1995
RITONAVIR (NORVIR) PI  HIV 1995
ENFUVIRTIDE FI  HIV 1996
OSELTAMIVIR  (TAMIFLU) NI  INFLUENZA  1997
LOPINAVIR PI  HIV 1998
ENTECAVIR NA  HEPATITIS  B 2000
PERAMIVIR NI  INFLUENZA  2000
ADEFOVIR NARTI  HBV 2000
ATAZANAVIR  PI  HIV 2000
DARUNAVIR  PI  HIV 2003
TARIBAVIRIN  NA  BROAD  SPECTRUM  2003
TELAPREVIR PI  HCV 2004
MARAVIROC  RA  HIV 2005
RALTEGRAVIR  II  HIV 2005
BOCEPREVIR  PI  HCV 2006
ELVITEGRAVIR  II  HIV 2006
NA: nucleoside analogue; NARTI: nucleoside analogue-reverse trancriptase inhibitor; UD: undetermined; PA: pyrophosphate analogue;
NNRTI: non-nucleoside analogue-reverse trancriptase inhibitor; NARTI: nucleoside analogue-reverse trancriptase inhibitor; PI: protease
inhibitor; FI: fusion inhibitor; NI: neuraminidase inhibitor; RA: receptor antagonist; II: integrase inhibitor.
HIV. The  science  of  antiviral  research  was  well  established
when  HIV/AIDS  appeared  as  a  major  viral  disease  in early
1980s.  An  increase  of  antiviral  therapy  studies  with  no  equal
took  place  when  the first  cases  of HIV  were  reported.  Azi-
dothymidine  (AZT),  among  other  antiviral  molecules  already
in  existence,  proved  to  have  selective  toxicity against  HIV.
However,  it was  during  the  treatment  of  HIV  that  medicine
confronted  new  obstacles.  The  concept of  resistant  strains
was  long  known  in the microbiological  world,  but  for the
young  and  developing  antiviral  terrene,  it was  an issue  of
little  importance  until  then.  HIV  was  one  of  the first  chronic
viral  diseases  discovered  to  have  a  considerable  impact
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Table  2  Summary  of  the  recent  treatment  guidelines  for  HCV  infection  therapy  [described  by  the American  Association  for  the  Study  of  Liver  Diseases  (AASLD),  Infectious
Disease Society  of  America  (IDSA)  and  the  International  Antiviral  Society  (IASUSA)].
HCV  genotype  Naïve  patientsb Non-responders  to  traditional  IFN-RBV
therapy
Resistant  to
Sofosbuvir
Resistant  to
traditional
therapy  and 1st
generation
protease
inhibitors
Patients  with
Cirrhosisb
1a Combination  of  Ledispavir  90  mg/sofosbuvir
400 mg  for  12  wks
Combination  of  Ledispavir  90  mg/sofosbuvir
400 mg  for  12  wks
Combination  of
Ledispavir
90  mg/sofosbuvir
400  mg  for  12
wks
Extend
treatment  for
24 wks
Paritaprevir  150  mg/ritonavir
100  mg/ombitasvir  25  mg/twice  daily  dose
of  dasabuvir  250  mg  and  RBVa for  12  wks
Paritaprevir  150  mg/ritonavir
100  mg/ombitasvir  25  mg/twice  daily  dose
of dasabuvir  250  mg  and  RBVa for  12  wks
Combination  Of
Ledispavir
90  mg/sofosbuvir
400  mg  plus
RBVa for  12
wks.
Extend
treatment  for
24 wks
Sofosbuvir 400  mg/Simeprevir  150  mg/RBVa
for  12  wks
Sofosbuvir  400  mg/Simeprevir  150 mg/RBVa
for  12  wks
Extend
treatment  for
24 wks
1b Ledipasvir 90  mg/sofosbuvir  400  mg  for  12
wks
Ledipasvir  90  mg/sofosbuvir  400  mg  for  12
wks
Ledispavir
90  mg/sofosbuvir
400  mg  plus
RBVa
Combination  Of
Ledispavir
90  mg/sofosbuvir
400  mg  for  12
wks
Extend
treatment  to
24 wks
Paritaprevir  150  mg/ritonavir
100  mg/ombitasvir  25  mg/twice  daily  dose
of  dasabuvir  250  mg  for  12  wks
Paritaprevir  150  mg/ritonavir
100  mg/ombitasvir  25  mg/twice  daily  dose
of dasabuvir  250  mg  for  12  wks
Combination  Of
Ledispavir
90  mg/sofosbuvir
400  mg  plus
RBVa for  12
wks.
Plus  RBV
Sofosbuvir 400  mg/Simeprevir  150  mg  for  12
wks
Sofosbuvir  400  mg/Simeprevir  150 mg  plus
RBVa for  12  wks
Extend
treatment  for
24 wks
2 Sofosbuvir 400  mg  and  RBVa for  12  wks Sofosbuvir  400  mg  and  RBVa for  12  wks  Extend
treatment  for
16 wks
Sofosbuvir 400  mg  and  RBVa plus  weekly
PEG-IFN  for  12  wks
3 Sofosbuvir  400  mg/RBVa Sofosbuvir  400  mg  and  RBVa for  12  wks
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Table  2  (Continued)
HCV  genotype Naïve  patientsb Non-responders  to  traditional  IFN-RBV
therapy
Resistant  to
Sofosbuvir
Resistant  to
traditional
therapy  and  1st
generation
protease
inhibitors
Patients  with
Cirrhosisb
Sofosbuvir  400  mg/RBVa plus  Weekly
PEG-IFN  for  12  wks
Sofosbuvir  400  mg  and  RBVa plus weekly
PEG-IFN  for  12  wks
4 Ledipasvir  90  mg/Sofosbuvir  400 mg  for  12
wks
Ledipasvir  90  mg/Sofosbuvir  400  mg  for  12
wks
Paritaprevir  150  mg/ritonavir
100  mg/ombitasvir  25  mg/and  RBVa for  12
wks
Paritaprevir  150  mg/ritonavir
100  mg/ombitasvir  25  mg/and  RBVa for  12
wks
Sofosbuvir 400  mg/RBVa for  24  wks Sofosbuvir  400  mg  plus  RBVa plus  Weekly
PEG-IFN  for  12  wks
Sofosbuvir  400  mg  plus  RBVa plus  Weekly
PEG-IFN  for  12  wks
Sofosbuvir  400  mg  plus  RBVa for  24  wks
5 Sofosbuvir  400  mg  plus  RBVa plus  Weekly
PEG-IFN  for  12  wks
Sofosbuvir  400  mg  plus  RBVa plus  Weekly
PEG-IFN  for  12  wks
Weekly  PEG-IFN  plus  RBVa for  48  wks Weekly  PEG-IFN  plus  RBVa for  48  wks
6 Ledispavir  90  mg/Sofosbuvir  400 mg  for  12
wks
Ledispavir  90  mg/Sofosbuvir  400  mg  for  12
wks
Sofosbuvir  400  mg  plus  RBVa plus  weekly
PEG-IFN  for  12  wks
Sofosbuvir  400  mg  plus  RBVa plus  weekly
PEG-IFN  for  12  wks
a RBV (Ribavirin) dosage is  weight based (1000 mg [<75 kg] and 1200 mg [>75 kg]).
All indications refer to daily doses unless is otherwise clarified in the text.
b Definitions for treatment criteria.42,43
(Treatment) Naïve patient: A person who has never undergone any HCV therapy.
-- Rapid Virologic Response (RVR): It  is defined as an undetectable HCV RNA at week 4 of  treatment.
-- Sustained Virological Response (SVR): It  is defined as undetectable HCV RNA  12 weeks (SVR12) or 24 weeks (SVR24) after treatment completion.
-- Non-response: Refers to a  patient who do not achieve undetectable HCV RNA  during the first 24 weeks of  treatment. There are two forms of  non-responders: Partial responders and
null responders.
-- Partial response: It is a sub-category of non-response and describes a decrease in HCV RNA levels by at least 2 Log10 at week 12  of treatment but detectable levels at week 24.
-- Null response: Is a sub-category of non-response and refers to the situation when a  patient does not  suppress their HCV RNA levels by  at least 2 Log10 by week 12  of  treatment.
-- Drug resistant: A patient who is Partial or Null responder to a  specific treatment for which a HCV ‘‘resistant’’ mutant remains immune making necessary to change the therapeutical
approach.
-- Liver Cirrhosis: Liver disease severity should be assessed prior to therapy. Identifying patients with cirrhosis is of particular importance as their prognosis is altered and their treatment
regimen may be adapted. Liver biopsy remains the reference method for grading the activity and histological progression (staging) of the disease (fibrosis and cirrhosis). Some non-invasive
methods can also be used: Assessment for Liver stiffness, muscle atrophy, patient skin, sclera and mucous; skin turgor, jaundice, spider angiomas and palmar erythema along with elevation
of liver enzymes (AST, ALT and LDH). Patients with liver cirrhosis must also be assessed for Hepatocellular Carcinoma.
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on  public  health.  Although  antiviral  research  and  develop-
ment  were  ignited  by  the HIV  threat,  many  HIV  patients
were  not  responsive  to  the  treatment.  The  discovery  of  AZT
was  followed  by  several  other  dideoxynucleoside  (ddN)  ana-
logues  (ddI,  ddC,  d4T,  3TC,  ABC,  FTC)  (Fig.  2).  All  these
NRTIs  act  in a similar  fashion;  after  their  phosphorylation
to  triphosphates,  they  interact  as  ‘chain terminators’  of
the  HIV-reverse  transcriptase,  thus  preventing  the formation
of  the  proviral  DNA.  Even  though  they had  great  success,
drug  resistance  forced  HIV  treatment  to evolve.  Today,  it
is  known  that  two  inevitable  and  important  consequences
of  antiviral  therapy  have to  be  taken  into  account  when
planning  a treatment  strategy  for  viral  chronic  diseases.
The  first  is that,  given  its nature,  long-term  antiviral  ther-
apy  automatically  selects  resistant  mutants  that  will  survive
and  become  dominant  strains.  Resistant  mutants  are  even
more  frequent  in viral  than  in bacterial  infection,  and  this
becomes  more  evident  when treating  chronic  viral  infections
such  as HIV  and HCV.35--37 For  viral  infections,  any  attempt
to  attack  the  virus’  metabolism  could  have an effect  on  host
cells.  It  is  evident then,  that  modifications  of  these two
aspects  of  antiviral  therapy,  could  improve  the results  of
treatment  for chronic  patients.  This  barrier  was  overcome
in  part  through  the  use  of  combinatorial  therapy.  In addi-
tion  to that,  the  concept  of  a broad  spectrum  or  at least  a
‘‘pangenotypic’’  antiviral  molecule  that  could  be  effective
on  a wide  range  of  viral  pathogens  is paradoxically  self-
defeating  if we  think  that  specificity  is  required  to  avoid  cell
toxicity  and  the  opposite  is  needed  to  broaden  the  spectrum
of  a  given  antiviral  molecule.  With  our  current  knowledge
on  viral  metabolism  and  host  interaction,  three  aspects  of
viral  infection  can  be  targeted  for  antiviral  treatment:  inhi-
bition  of  viral  genes  and proteins,  blocking  of host  genes  and
enzymes  that  interact  with  viral  counterparts,  and  modula-
tion  of  host  metabolic  pathways  involved  in  the  virus  life
cycle.
The  challenges  of  fighting Hepatitis  C
As  we  mentioned  before,  a  new  era of  therapeutics  is
currently  emerging  for  Hepatitis  C  treatment,  since  sev-
eral  other  direct-acting  HCV  antiviral  drugs  are being
developed  (Protease  inhibitors:  faldaprevir,  asunaprevir,
danoprevir,  vaniprevir,  ABT-450-ritonavir,  MK5172,  GS-9451;
NS5A  inhibitors:  ledipasvir,  ombitasvir,  GS-5816,  PPI-668,
MK-8742  and  daclatasvir;  NS5b  inhibitors:  mericitabine,
VX-135,  dasabuvir,  BMS-791325,  GS-9669),  which have  been
shown  to reduce  viral  RNA  levels,  reaching  SVR  in  up  to
95%  of  the  treated  patients.38,39 However,  there  are  several
challenges  to  be  addressed  to  combat  HCV  using  new  drugs.
DAA’s  directly  attack  the Hepatitis  C  virus  and,  similar  to
some  of  the  drugs  used to  treat  HIV,  these new molecules
target  the  enzymes  needed  for  viral  protein  processing;  the
virus  should  counterpart  this effect  (Fig.  2).  Based  on  that,
HCV  genetic  variability  and  drug resistance  are the bigger
obstacles  that  DAAs  must  overcome.  HCV  has  a  high  rate
of  replication,  with  1012 virions  produced  daily,  along  with
an  equally  high  mutation  rate,  meaning  that,  for any  given
drug,  there  are  already  resistant  mutants  present  on  the
infected  subject  that would  ultimately  render  single  drugs
useless.  However,  Hepatitis  C  resistance  may  be  delayed  or
prevented  by  using  combinations  of  potent  antiviral  drugs
without  cross-resistance  profiles  and optimizing  patient
adherence  to  therapy.38 On  the other  hand,  accessibility
to  the  new  and  approved  HCV  therapies  is  a  challenge  in
combating  the Hepatitis  C,  mainly  because  of  the  high
cost  of the combined  treatments  (between  100,000  and
250,000  USD).  Availability  and accessibility  of  new protease
inhibitors  (PI),  telaprevir,  boceprevir,  simeprevir,  and  the
recently  approved  RNA  polymerase  inhibitor  (RPI)  sofosbuvir
depends  on  the  region  where  patients  are located  and  their
access  to  governmental  health  programs.  In  most  countries,
accessibility  to  these  drugs  is  possible  only for  those  patients
who  can  afford  treatment  for themselves,  as  public  health
systems  do not  yet  have  policies  for  application  of  the new
HCV  therapy  to  the general  population  through  insurance
systems.40 This  will  likely  require  concerted  public  and
political  mobilization  to  pressure  originator  companies  to
reduce  prices  and  stimulate  generic  competition.  In  addi-
tion,  lower  prices  could  make  widespread  access  to  HCV
treatment  possible  in low and middle  income  countries.
Where we stand today
After  almost  20  years  since  HCV’s  discovery,  today  we
account  for  a  solid-yet-not-completely  effective  treat-
ment  landscape  to  fight hepatitis  infection.  First,  modern
biomolecular  diagnostic  tools  are  used  to  determine  geno-
type  and  viral  load  as  a base  to  design  an accurate
therapeutic  regimen;  second,  viral load  dynamics  is moni-
tored  in order  to  determine  drug  resistance,  and  third  the
liver’s  state  and the presence  of infection  are assessed  in
patients  who  have  completed  the therapy.  In  an effort  to
provide  a condensed  set  of  treatment  guidelines,  the Amer-
ican  Association  of  Liver  Disease  (AASL),  Infectious  Disease
Society  (IDSA)  and the  International  Antiviral  Society  (IAS-
USA)  generated  the Guidelines  for  HCV  infection  treatment
which  are based  on  patient’s  previous  exposure  to  treat-
ment,  HCV  genotype,  relapsing  profile  and hepatic  status.41
In Table  2  we  show  a  compendium  of  the  recent treatment
guidelines  for HCV  infection  therapy.  It  is  important  for
physicians  to  evaluate  patient  clinical  history  (naïve  or  not),
HCV  genotype,  treatment  effectiveness  and HIV  co-infection
in order  to  avoid  unwanted  drug interactions.
Conclusions  and perspectives
Antiviral  therapy  is  a  well-established  discipline  with
a  promising  future.  Based  on  economic,  scientific  and
medical  interest,  and a  continuous  need  for  new  drugs  to
avoid  resistance,  it is  most  likely  that  the  development
of  antiviral  drugs  over the next 20  years  will  be  focused
on  HIV  and  HCV.  Today,  well-established  diagnostic  and
study  systems  are available  for  HCV  and  other  viruses.  New
targets  against  HCV,  such as inhibitors  for  the scavenger
receptor  type  B1 (SR-B1)  and CD81,  neutralizing  antibodies
against  the viral  glycoproteins  and  the  NS5B  polymerase,
as  well  as  the  NS2/3  auto-protease,  the  NS3  helicase,  and
non-enzymatic  targets  such  as  NS4B  and  NS5A  proteins  are
in  development  (Fig.  1).  Other potential  drugs  targeting
HCV  replication  include  compounds  active  against  the  IRES
element  and  antisense  inhibition.  As  mentioned  before,
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virus  factors  are  not  the only  potential  targets  for  inhibition,
but  host  targets  are  as  well,  including  microRNAs,  cellular
receptors,  adhesion  molecules  and  cyclophilins.  For  the
near  future,  a combination  of  host  and  viral  inhibitors  will
provide  a  variety  of  drug regimes  appropriate  for  different
patients  that  could  lead to  interferon-free  therapies  that
can  consistently  clear  the infection.
A  new  era  of  HCV  treatment  and  the increasing  knowl-
edge  about  viruses  and  their  mechanisms  of infection,
combined  with  the  rapid  discovery  of  novel  antiviral  strate-
gies  and  techniques,  will speed  up  the development  of  novel
antiviral  drugs.
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